A dramatic rise in type 2 diabetes has led to an increase in peripheral neuropathy. New research published in Nature from the lab of Clifford Woolf, led by Sara Hakim, at Boston Children's Hospital ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Most scientists accept that it involves activation and sensitization of the trigeminovascular system, which includes the sensory peripheral projections to the pain-producing dura mater ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...

"Smokers face an elevated risk of developing an array of cardiovascular diseases, and many require advanced interventional ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

FORT LAUDERDALE, FL / ACCESSWIRE / February 11, 2025 / ZEO ScientifiX, Inc. ('ZEO' or the 'Company') (OTCQB:ZEOX), a clinical-stage biopharmaceutical company fo ...

FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and developme ...